An observational study in Neoplasms, sponsored by Bayer. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Bayer · Observational
The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.
Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period. It will consist of mCRPC patients and potentially some other patient groups in whom Xofigo may be used off-label including women, children, cancer patients having bone metastasis with a diagnosis other than CRPC, and patients with repeated courses of treatment or in excess of those recommended in the label. This study will be based on data extracted from two pre-established data sources: 15 nuclear medicine centers across Sweden and the Swedish National Cancer Registry.
Exclusion Criteria:
This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden. This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period.
Other: Radium-223 dichloride (Xofigo, BAY88-8223)
Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
Proportion of men with metastatic castration resistant prostate cancer (mCRPC) of Xofigo use
Time frame: Up to 2 years
Proportion of being women of Xofigo use
Time frame: Up to 2 years
Proportion of being children of Xofigo use
Time frame: Up to 2 years
Proportion of bone metastasis but having a diagnosis of other cancer than mCRPV
Time frame: Up to 2 years
Dosage of Xofigo (kBq/kg)
Time frame: Up to 2 years
Proportion of participants of dose outside label recommendation
Time frame: Up to 2 years
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer